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Regenerative efforts typically focus on the delivery of single
factors, but it is likely that multiple factors regulating distinct
aspects of the regenerative process (e.g., vascularization and stem
cell activation) can be used in parallel to affect regeneration
of functional tissues. This possibility was addressed in the context
of ischemic muscle injury, which typically leads to necrosis and loss
of tissue and function. The role of sustained delivery, via injectable
gel, of a combination of VEGF to promote angiogenesis and
insulin-like growth factor-1 (IGF1) to directly promote muscle
regeneration and the return of muscle function in ischemic rodent
hindlimbs was investigated. Sustained VEGF delivery alone led to
neoangiogenesis in ischemic limbs, with complete return of tissue
perfusion to normal levels by 3 weeks, as well as protection from
hypoxia and tissue necrosis, leading to an improvement in muscle
contractility. Sustained IGF1 delivery alone was found to enhance
muscle ﬁber regeneration and protected cells from apoptosis.
However, the combined delivery of VEGF and IGF1 led to parallel
angiogenesis, reinnervation, and myogenesis; as satellite cell
activation and proliferation was stimulated, cells were protected
from apoptosis, the inﬂammatory response was muted, and highly
functional muscle tissue was formed. In contrast, bolus delivery of
factors did not have any beneﬁt in terms of neoangiogenesis and
perfusion and had minimal effect on muscle regeneration. These
results support the utility of simultaneously targeting distinct
aspects of the regenerative process.
alginate | insulin-like growth factor-1 | tissue engineering | VEGF | satellite
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The long-term goal for muscle regeneration strategies is torecover the contractile properties of the injured muscles.
Under normal conditions, skeletal muscle can repair itself by
removing damaged myoﬁbers and synthesizing new muscle ﬁbers
to restore functional contractile properties (1). After necrosis of
damaged muscle ﬁbers, an inﬂammatory response is initiated (2)
leading to the phagocytosis of the injured myoﬁbers and the
activation of the normally quiescent population of satellite cells
(3, 4). The activated satellite cells proliferate, migrate to the site
of injury, fuse and, differentiate to form new myoﬁbers (5, 6).
However, muscle degeneration in the context of tissue ischemia,
advanced age (7), severe injuries, or in the context of genetic
defects [e.g., muscular dystrophy (8)], may lead to impaired
healing, permanent loss of muscle mass, disease progression, and
functional deﬁciency. Given that 6 million Americans are diag-
nosed with musculoskeletal diseases each year, the potential for
improved skeletal muscle repair strategies is signiﬁcant (9, 10).
The main strategies currently pursued for skeletal muscle
regeneration consist of cell therapies, drug delivery strategies, or
a combination of both approaches. Cell therapies, either by
direct injection of cells into the damaged tissues (11) or the
transplantation of progenitor cells on polymeric scaffolds (12,
13), are typically limited by the death of the majority of the
transplanted cells and/or poor integration of the templated tis-
sues with the host tissue. Most of the drug delivery strategies thus
far have yielded limited success, most likely related to rapidly
depleted local concentrations, inappropriate gradients, and/or
loss of bioactivity of growth factors (GFs) resulting from bolus
drug delivery and rapid degradation in the inﬂammatory in vivo
environment of the damaged tissue. Biodegradable polymeric
systems have been developed to provide localized and sustained
GF release (14). However, it may be necessary to deliver mul-
tiple morphogens acting in distinct aspects of the tissue re-
generation process to drive muscle regeneration to completion,
as previously reported for other tissues (15).
The hypothesis underlying this study is that localized and
sustained presentation of factors that modulate both angio-
genesis and myogenesis can stop or reverse muscle injury
resulting from tissue ischemia. Many previous studies have
examined vascular regeneration after ischemic injury, but the
purpose of this study was to investigate instead the effect of GF
delivery on the regeneration of the skeletal muscle. The sus-
tained release of VEGF from polymeric delivery systems has
been widely implicated in neovascularization and was previously
demonstrated to enhance blood vessel formation and perfusion
within ischemic muscle tissue (15, 16). Several recent studies
have demonstrated that VEGF leads to better maintenance of
skeletal muscle tissue in mouse models of muscular dystrophy,
suggesting that VEGF may also play a role in muscle re-
generation after injury (17–19). Other ﬁndings highlight the
possibility that VEGF’s ability to promote vascularization could
increase the availability of blood vessel–associated stem cells
capable of participating in muscle regeneration (20–22). How-
ever, a direct improvement in muscle regeneration has not been
documented. In addition, although VEGF is a well-established
proangiogenic regulator, its presence is likely not sufﬁcient to
recapitulate the complex muscle regeneration process, because
this requires the activation and differentiation of the muscle’s
stem cell population to generate new muscle.
Various stem cell populations are capable of building new
muscle ﬁbers (8, 23–25), but satellite cells, an adult stem cell
population associated with myoﬁbers and localized within the
basal lamina of the muscle ﬁbers, are believed to be primarily
responsible for muscle regeneration (6). The activation of sat-
ellite cells is ﬁnely regulated via a number of biochemical and
biomechanical cues, including both inﬂammatory cytokines (e.g.,
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IL-4, leukemia inhibitory factor, TGF-β, IL-6, and TNF-α) (26),
and GFs, including hepatocyte growth factor, ﬁbroblast growth
factor-2 (25), insulin-like growth factors (1), and GDF8/myo-
statin (27). Insulin-like growth factor-1 (IGF1) plays a key mod-
ulatory role in muscle growth and regeneration, acting during all
of the stages of regeneration (27). The binding of IGF1 to type I
receptors has been shown to activate three different intracellular
signaling pathways—the MAP kinase pathway, the PI3-K pathway,
and the calcium–calmodulin-dependent protein kinase pathway—
leading to the activation and proliferation of the satellite cells,
their terminal myogenic differentiation (indicated by MyoD and
myogenin levels), increased protein synthesis, myoﬁber survival,
and myoﬁber hypertrophy (27).
This study investigated a potential interplay between VEGF and
IGF1 in ischemic muscle regeneration, and the possibility that dual
sustained delivery of these two critical morphogens could induce
the regeneration of functional muscle in ischemic hindlimbs. The
impact of the distance of the muscle from the factor delivery site
on the regeneration process was also examined by analyzing dis-
tinct muscles in the hindlimbs. As targets for these experiments, we
chose the gracilis and tibialis muscles, respectively corresponding
to the muscle site of injection and a muscle distant to the site of
polymer placement. The ultimate goal of this approach is to pre-
serve the local progenitor cells from apoptosis and necrosis during
the degeneration process, and instead to activate the progenitor
cells to enter the proliferative phase and differentiate into con-
tractile muscle ﬁbers to regenerate functional tissue.
Results
Sustained VEGF and IGF1 Presentation Enhance Muscle Size and Limb
Vascularization. An ischemia injury was selected for these studies
after analysis of the spontaneous recovery of muscle mechanical
function subsequent to various types of injuries, including partial
laceration, cryoinjury, and notexin injection (Fig. S1). Ischemia
led to the greatest loss of muscle function, as compared with the
other injury models, and the least spontaneous return of function.
Mice were treated at the time of ischemia induction with an
injectable, degradable (28) alginate gel (Fig. 1A). In vitro, after an
initial burst, VEGF was released in a sustained manner over time,
as previously described, whereas IGF, owing to its smaller size (7.5
kDa) and its non–heparin-binding nature, showed a faster release;
≈80% of the total IGF loaded was released in the ﬁrst 24 h (Fig.
1B). The following ﬁve interventions were analyzed: (i) blank al-
ginate gel, (ii) alginate gel delivering VEGF (3 μg), (iii) alginate
gel delivering VEGF and IGF1 (3 μg each), (iv) alginate gel de-
livering IGF1 (3 μg), and (v) bolus delivery of VEGF and IGF1 (3
μg each) in PBS.
Signiﬁcant muscle loss was noted at 7 weeks after surgery with
blank gel treatment (Fig. S2 E and F), whereas injured muscles
treated with gel containing both GFs were grossly larger. Quan-
tiﬁcation of the weight of these muscles revealed insigniﬁcant
changes with gel releasing either VEGF or IGF alone, or with the
saline bolus treatment, whereas statistically signiﬁcant increases of
26% ± 11% and 30% ± 22% occurred for the tibialis (distant to
gel injection) and gracilis muscles (site of gel injection) (Fig. 1 C
and D), respectively, receiving gel releasing both GFs as compared
with the blank treatment. The large standard deviations in the
gracilis muscle analysis were due to the difﬁculty in isolating the
gracilis muscle from the other tightly associated muscles.
Because the effects of VEGF delivery on muscle regeneration
were likely mediated by its effects on angiogenesis, the level of
muscle hypoxia, perfusion of ischemic tissues, and tissue necrosis
were next analyzed. Immunohistochemical analysis of tibialis and
gracilis muscle tissues revealed that alginate/VEGF and alginate
VEGF/IGF1 increased muscle blood vessel densities, as com-
pared with injection of a blank vehicle or bolus delivery of VEGF/
IGF (Fig. S2 A and C). In particular, at 7 weeks, VEGF delivery
from the gels resulted in an approximately 2-fold increase in
vessel density in tibialis and 3-fold increase in the gracilis muscle,
as compared with the ischemic hindlimb treated with the blank
alginate (Fig. S2 B and D). IGF delivery alone had no signiﬁcant
effect on vascularization in the gracilis muscle (Fig. S2D) and a
modest effect in the tibialis (Fig. S2B). The bolus delivery had no
effect on blood vessel densities, as compared with controls.
A laser Doppler perfusion imaging (LDPI) system was used to
quantify perfusion (Fig. 2A, Fig. S3A). The regional blood ﬂow
was reduced immediately after surgery to ≈20% of normal in all
conditions, as expected (Fig. 2A). Alginate gel–only treatment led
to a slow increase in reperfusion over time, and the ischemic limbs
for the most part remained necrotic (Fig. 2B). Bolus delivery re-
sulted in little difference from the no-treatment control or blank
alginate injection. In contrast, VEGF and dual GF delivery from
the vehicle led to a ﬁnal recovery of, respectively, 80% and 95% of
normal limbs. In particular, animals treated with alginate gels
delivering VEGF/IGF1 showed a marked increase in blood ﬂow
starting around the 4th week after the injury, and an additional
20% increase at 7 weeks compared with the control (Fig. 2A).
The level of tissue necrosis (Fig. 2B) was also quantiﬁed by
visual observation. Hindlimb ischemia led to severe toe or foot
gangrene in control animals, but treatment with alginate gel with
VEGF and VEGF/IGF largely spared the limbs from necrosis.
Protection of myoﬁbers from hypoxia was also observed with
alginate gel VEGF and VEGF/IGF delivery (Fig. S3B).
VEGF and IGF1 Induce Myoblast Proliferation and Protect Against
Apoptosis. Immunostaining of tissue sections against the pro-
liferation-associated protein Ki67 was performed to determine
cell proliferation activity at early (2 weeks) and late (7 weeks)
Fig. 1. (A) Photograph of the injectable alginate gel (color due to medium used to reconstitute alginate). (B) VEGF and IGF1 release kinetics from gels in
vitro. (C and D) Weight of the nonoperated (control) tibialis (C) and gracilis (D) muscles at 7 weeks, compared with the muscles after ischemic injury and
treatment with blank alginate gel (alginate gel), alginate gel delivering VEGF (gel/VEGF), alginate gel delivering VEGF and IGF1 (gel/VEGF+IGF), alginate gel
delivering IGF1 (gel/IGF), and bolus delivery of VEGF and IGF1 in PBS (bolus).Values represent mean ± SD (n = 6) in all graphs. At *P < 0.05 level the means are
signiﬁcantly different compared with the control and the blank alginate.
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times. Abundant expression of Ki67 was detected in muscle tis-
sues receiving alginate gels releasing VEGF alone and VEGF/
IGF1 in both tibialis (Fig. S4 A and B) and gracilis muscles (Fig.
S4 C and D) at 2 weeks (Fig. S4 A and C) and 7 weeks (Fig. S4 B
and D). A less-pronounced increase was observed with alginate
gel delivering IGF, whereas no proliferation was observed in
muscles treated with the blank vehicle. Furthermore, triple im-
munoﬂuorescence for CD31 (red), Ki67 (green), and DAPI
(blue) for nuclear staining suggests that endothelial cells and
other cell types, presumably myoblasts, proliferated at early
stages of the regenerative process (Fig. S5). TUNEL analysis was
performed to measure apoptosis in the regenerating muscles at 2
weeks after ischemia. Whereas signiﬁcant apoptosis was ob-
served in the blank vehicle group (Fig. S6A), apoptosis was re-
duced in the muscles treated with alginate delivering VEGF (Fig.
S6B) and was signiﬁcantly lower with vehicles delivering IGF
alone (Fig. S6C). The combination of the two GFs was partic-
ularly effective in combating ischemia-induced apoptosis (Fig.
S6D). Apoptosis was virtually absent in contralateral normo-
perfused muscles (Fig. S6E), as expected.
Muscle Regeneration Enhanced by VEGF and IGF1, Along with
Reduced Fibrosis. To directly analyze muscle regeneration, the
mean diameter of regenerated myoﬁbers and number of centrally
located nuclei in the resolving muscle tissue were quantiﬁed (Fig.
3). The mean diameters of muscle ﬁbers were quantitatively
greater in muscles treated with alginate delivering both GFs
compared with alginate delivering only VEGF or IGF1 or the two
GFs in bolus saline, in both tibialis (Fig. 3 A and B) and gracilis
muscles (Fig. 3D and E). The tibialis muscles treated with alginate
delivering VEGF or IGF1 alone showed an ≈10% increase in
average diameter, whereas codelivery of both GFs led to a 25%
increase in the diameter of regenerating ﬁbers compared with the
blank alginate gel, and a 19% increase compared with gel/VEGF
(P < 0.05) (Fig. 3A). An increase was also observed in gracilis
muscle with VEGF/IGF delivery from the alginate gels (Fig. 3D).
At 2 weeks after injury the tibialis muscle ﬁbers in the injury group
treated with VEGF or IGF1 alone also showed an ≈40% increase
in centrally located nuclei, vs. a lesser increase of 30% with bolus
factors delivery as compared with the blank. The two factors in
combination with alginate delivery led to a 53% and a 39% in-
crease in centrally located nuclei, as compared with the blank
alginate or alginate delivering VEGF alone (Fig. 3B). The number
of centrally located nuclei in the gracilis ﬁbers (Fig. 3E) treated
with alginate delivering both GFs increased ≈70% and 20%, re-
spectively, when compared with either the blank alginate or with
alginate delivering VEGF only. Representative cross and longi-
tudinal microsections of tibialis tissue highlight the increase in
centrally located myonuclei in the ischemic muscles treated with
alginate delivering both GFs (Fig. 3C). Analysis of the muscle
ﬁber types conﬁrmed an active regenerative process induced by
GF delivery. Type IIC ﬁbers were noted at early times (3 days)
after injury with delivery of GF from the gel but were not present
in uninjured control muscles or uninjured muscles treated with
gel/GF (Fig. S7). Furthermore, analysis of injured muscle treated
with gel delivering VEGF revealed a signiﬁcant increase in my-
ogenin-positive cells, which contrasts with few myogenin-positive
cells in control, uninjured muscle (Fig. S8), also supporting an
active muscle regeneration process. Furthermore, analysis for the
expression of the activated satellite cell marker Pax7 demon-
strated an increase in Pax7-positive cells in the injured muscle
Fig. 2. Blood perfusion and tissue necrosis. (A) LDPI blood
perfusion analysis of C57 mice hindlimbs treated with blank
alginate gel, alginate gel delivering VEGF, alginate gel de-
livering VEGF and IGF1, alginate gel delivering IGF1, and
bolus delivery of VEGF and IGF1 in PBS. *P < 0.05 vs. blank
alginate gel and bolus; mean values are presented with SD.
(B) Ischemic hindlimbs treated with blank alginate gel, algi-
nate gel delivering VEGF, and alginate gel delivering VEGF
and IGF1 were visually examined to determine the severity of
hindlimb ischemia at 1, 3, and 7 weeks after ligation.
Fig. 3. Analysis of muscle regeneration. Diameter (A and D) and number of
centrally located nuclei (B and E) of regenerating ﬁbers at 2 and 7 weeks after
the induction of ischemia were quantiﬁed. ANOVA statistical tests were per-
formed on all data sets. *P < 0.05 vs. blank alginate gel. (C) Representative
photomicrographs of tibialis tissue sections from ischemic hindlimbs at post-
operative week 2, stained with H&E [cross and longitudinal (long) section,
respectively, of contralateral hindlimb and ischemic muscles treated with al-
ginate vehicle delivering VEGF/IGF1]. Scale bars, 50 μm.



















tissue treated with gel delivering VEGF (Fig. S8), supporting
satellite cell activation with GF delivery.
Injured muscle tissue treated with blank alginate demon-
strated signiﬁcant interstitial ﬁbrotic tissue (Fig. S9). Control
(nonoperated) limbs demonstrated little ﬁbrosis, as expected.
However, limbs treated with alginate gel delivery of both GFs
exhibited a signiﬁcant decrease in ﬁbrosis. A less-pronounced
reduction of ﬁbrosis was observed with the two GFs delivered
alone. Conversely, in the bolus injection condition a large con-
tent of ﬁbrotic tissue was formed.
Growth Factor Delivery Promotes Earlier Regeneration of Damaged
Neuromuscular Junctions. Induction of ischemia in the hindlimb
and treatment with a blank hydrogel led to a signiﬁcant loss of
innervation at the neuromuscular junction (NMJ) in the tibialis
muscle 7 days after injury in control mice (Fig. 4A); by day 14
complete reinnervation had occurred, and NMJs appeared nor-
mal (Fig. 4E). In contrast, muscles treated with either VEGF
alone (Fig. 4B), IGF1 alone (Fig. 4C), or VEGF/IGF1 (Fig. 4D)
had completely reformed NMJs, and no damage to receptors or
muscle ﬁbers was observed at 7 days.
Dual Gel Delivery of VEGF and IGF1 Enhances the Contraction Force of
Damaged Muscles. Finally, to test whether muscle changes induced
by GF delivery would correspond to increased function, the con-
tractile force of the muscles was analyzed. The weight normalized
tetanic force of the tibialis (Fig. 5A) and gracilis muscles (Fig. 5B)
were measured after maximal tetanic stimulation. Muscles treated
with gel delivering both GFs showed a signiﬁcant increase above
normal values in the tetanic force at 2 weeks after surgery (2.3-
and 7.9-fold increase, respectively, for tibialis and gracilis muscles,
when compared with the blank) followed by a decrease toward the
normal value at 7 weeks. Animals receiving alginate delivering
VEGF alone showed a similar trend, but the increase in the force
of contraction was less pronounced. In particular, at 2 weeks a 1.6-
and 5.7-fold increase was measured in tibialis and gracilis muscles,
respectively, compared with alginate gel only. In contrast, the
animal receiving alginate gel without GFs had a markedly lower
contractile function at all time points.
Discussion
The results from these studies suggest a beneﬁcial interplay
between VEGF and IGF1, when delivered appropriately, in
enhancing skeletal muscle regeneration, revascularization, rein-
nervation, and gain of function after ischemic injuries. Past
therapies to regenerate ischemic tissues typically relied on bolus
delivery or systemic administration of single GFs. VEGF speciﬁ-
cally has been widely used as a potent proangiogenic initiator in
many strategies to treat ischemic diseases (29). However, the
impact on salvaging and driving regeneration of ischemic muscle
has not been addressed (30). Moreover, an extensive body of lit-
erature supports a role for IGF1 in regulating the establishment
and maintenance of the mature muscle phenotype in normal and
regenerating muscle tissue both in vitro (28, 31) and in vivo (32,
33). In particular, IGF1 has been implicated in early and late
stages of muscle developmental processes, playing ﬁrst a role in
inducing myoblast proliferation and subsequently promoting
myogenic differentiation (5, 34). Past approaches to exploit GF
signaling in muscle regeneration typically used bolus GF delivery,
which leads to rapid depletion of the factors in the target tissue.
Supraphysiologic concentrations of GFs are used in an effort to
offset this issue, potentially leading to unwanted side effects (35).
Sustained VEGF delivery alone from alginate gels had a sig-
niﬁcant impact on angiogenesis and tissue perfusion but a less
pronounced effect on muscle regeneration (17–19). These results
are in accord with previous reports that the sustained and con-
trolled release of VEGF from both a poly(lactide-co-glicolide)
(PLG) (15) and the same injectable alginate-based vehicle (16)
stimulated angiogenesis, returned perfusion to normal levels,
and prevented necrosis in ischemic hindlimbs. VEGF has also
recently been implicated in muscle regeneration (36) and muscle
reinnervation via a direct neuroprotective and neurodirecting
effect (37, 38). The contractile activity of skeletal muscle, and
hence its functionality, are regulated by the nervous system, and
loss of innervation leads to a decrease in satellite cell number
and muscle atrophy (38). The results of this study suggest that
delivery of VEGF alone has profound effects on muscle re-
generation, because increases in the diameter of regenerating
ﬁbers and the number of centrally located nuclei in muscle ﬁbers,
both hallmarks of regenerating myoﬁbers (39, 40) (Fig. 3), were
found with gel/VEGF delivery. These results are consistent with
past reports that VEGF may play an important role in muscle
maintenance and regeneration (17–19). The contractile proper-
ties of the injured muscle (Fig. 5) were also improved with ap-
propriate VEGF delivery.
IGF1 delivery alone from alginate gels was found to have a
modest effect on muscle ﬁber regeneration and cell protection
from apoptosis. These data are consistent with previous studies in
which increased levels of IGF1 augmented tissue DNA content
(resulting from activation of satellite cells) (40–42) and muscle
protein synthesis within existing myoﬁbers (43–46). Gel/IGF1
Fig. 4. Analysis of reinnervation. (A–D) Photomicrographs of the NMJ in the tibialis muscle stained with bungarotoxin at 7 days after induction of ischemia
and treatment with blank alginate gel (A), alginate gel delivering VEGF (B), alginate gel delivering IGF1 (C), or alginate gel delivering VEGF and IGF1 (V+I, D).
(E) Quantiﬁcation of the sites of overlap of motor neuron axon (yellow) and endplate (red) as a site of reinnervation. Values are mean ± SD. *P < 0.05.
Fig. 5. Functional properties of skeletal muscles. Tetanic force of the an-
terior tibialis (A) and gracilis (B) muscles of mice was measured at 2 and 7
weeks after induction of ischemia and treatment. Tetanic force was nor-
malized to each muscle’s weight to obtain weight-corrected speciﬁc force.
Mean values are presented with SD. *P < 0.05 vs. control limb and blank
alginate gel; **P < 0.05 level vs. blank alginate gel.
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delivery alone also induced neoangiogenesis in the tibialis muscle
and to a lesser effect in the gracilis muscle. This effect was likely
secondary to the effects of IGF1 on the muscle cells. The delivery
approach used in this study resulted in an initial burst delivery of
this factor, likely leading to a rapid diffusion of the factor from the
site of the injection. A more sustained delivery of IGF1 may more
signiﬁcantly increase muscle regeneration.
Strikingly, dual VEGF/IGF1 delivery from gels had a syn-
ergetic effect on the regenerative parameters in both of the
analyzed muscles. In particular, both the mean ﬁber diameter
and the number of centrally located nuclei in the ﬁbers (Fig. 3)
were signiﬁcantly enhanced with alginate delivery of both GFs,
showing a more pronounced response in the muscle where the
gel was injected (gracilis). These results were qualitatively vali-
dated by an increased number of myoblasts found in an active
proliferative state, the presence of myogenin and Pax7-positive
cells (Fig. S8), type IIC muscle ﬁbers (Fig. S7), and decreased
cell apoptosis (Fig. S6). These results suggest an enhancement in
myoblast recruitment for neomuscle formation, which is con-
sistent with the larger size and mass of these muscles (Fig. 1, Fig.
S2 E and F). However, the enhanced myogenic regeneration in
response to VEGF and VEGF/IGF sustained delivery could also
be explained by recent ﬁndings (20–22) suggesting the existence
of myogenic precursors distinct from satellite cells (e.g., pericyte-
derived cells and myoendothelial cells) endowed with multi-
lineage potential, including high muscle regenerative potential.
Stimulation of angiogenesis may increase the pool of myogenic
stem cells that are available to drive muscle regeneration. Fur-
thermore, the combination of VEGF/IGF1 was shown to alle-
viate ischemia, with a return to normal hemodynamic levels and
a better prevention of the necrosis associated with ischemia.
Previous in vivo studies, using this same animal model, con-
ﬁrmed that the sustained delivery of bioactive GFs (VEGF) from
this gel system led to long-term (>15 days) elevated muscle levels
(16). This contrasted with bolus delivery: the factor concen-
tration fell to undetectable levels within hours after that delivery
approach. The sustained presence of factors enabled by alginate
gel delivery correlated with the long-term alterations in the
vascular and muscle tissue noted in the present study with gel
delivery, as contrasted to bolus delivery. However, the precise
relationship between GF presence and regeneration remains
unclear. This relationship should be probed in the future by re-
moving the gels at various times after implantation and/or pro-
viding multiple gel injections at various time points.
Because the peripheral nervous system is also affected by ische-
mic injury, the effects of sustainedGFdelivery on innervation at the
NMJ were also examined. Ischemia is known to result in loss of
NMJ innervation via degeneration of the presynaptic axon, and this
was observed in the injury model used in this study. In the absence
of GFs, axons required 2 weeks to fully regenerate. In contrast,
treatment with gels releasing either IGF1 alone, VEGF alone, or
IGF1 andVEGF accelerated regeneration of damaged NMJs. IGF
has been shown to have neuroprotective effects inmouse models of
amyotrophic lateral sclerosis, which is believed to be mediated by
satellite cells andmaturemuscle ﬁbers (32, 47, 48). Upregulation of
IGF in thesemodels also leads to a decrease in ubiquitin expression
(49), suggesting that the mechanism of IGF neuroprotection may
be inhibition ofWallerian degeneration (50, 51). The reinnervation
observed upon treatment with VEGF and IGF1 suggests that gel
delivery of factors may be useful in treating the neurologic com-
plications of chronic ischemia. Together these effects likely played
important roles in the early recovery of themouse locomotive skills.
Most strikingly, tetanic force measurements of the tibialis (Fig.
5A) and gracilis (Fig. 5B) muscles demonstrated a signiﬁcant in-
crease to above-normal levels with dual delivery of GFs at 2
weeks, with a 2 fold- and an 8-fold increase in force for tibialis and
gracilis respectively, vs. the untreated (blank alginate) hindlimb,
indicating functional muscle regeneration. Conversely, a sig-
niﬁcant decrease toward the normal value was observed after 7
weeks, likely indicating an adaptation to normal physiologic re-
quirements for these muscles. Increased muscle strength was also
associated with a decrease in ﬁbrotic tissues (Fig. S9). Previous
studies have shown a role of IGF1 in ﬁnely modulating the balance
between inﬂammation and regeneration, which is crucial for ac-
celerating the functional recovery of injured muscle (52). After
muscle injury, an inﬂammatory response is activated, but pro-
longed accumulation of ﬁbrotic tissue limits muscle cell replace-
ment, leading to less strength and functional depletion compared
with normal muscles. The increased force observed in muscles
with GFs delivery may also be related to enhanced reinnervation,
although the speciﬁc mechanisms by which these GFs inﬂuence
reinnervation remain to be deﬁned (53, 54).
In summary, the dual delivery of VEGF/IGF1 from an
injectable biodegradable hydrogel leads to a complete functional
recovery of ischemic injured skeletal muscle. This strategy to
enhance skeletal muscle regeneration may provide a therapeutic
option for treatment of muscle damaged from a variety of causes.
In the future, additional factors that play roles in regulating the
proliferation and differentiation of satellite cells and cells could
also be incorporated and delivered with this system. More
broadly, the concept of simultaneously stimulating the regener-
ation of the vascular and the parenchyma of damage tissues will
likely be useful in many situations.
Materials and Methods
Growth Factor Incorporation and Release Kinetics. Ultrapure MVG alginate was
purchased from ProNova Biomedical. Gels were formed from a combination of
polymer molecular weights as previously described (16). Alginates were re-
constituted in EBM-2 (Cambrex) to obtain a 2%wt/vol solution before gelation
and cross-linked with aqueous slurries of a calcium sulfate (0.21g CaSO4/mL
dH2O) at a ratio of 25:1 (40 μL of CaSO4 per 1 mL of 2% wt/vol alginate sol-
ution). Alginates were premixed with recombinant human VEGF165 protein
(generously provided by the Biological Resources Branch of the National
Cancer Institute) and/or with recombinant human IGF1 (R&D Systems), at a
ﬁnal concentration of 60 μg/mL for each protein; in vitro release kinetics were
measured using ELISA.
Animals and Surgical Procedures. Animal work was performed in compliance
with National Institutes of Health and institutional guidelines. Female C57BL/6J
mice (aged 6 to 7 weeks; Jackson Laboratories) were anesthetized with an i.p.
injection of ketamine 80 mg/kg and xylazine 5 mg/kg before all surgical pro-
cedures. Hindlimb ischemia was induced by unilateral external iliac and femoral
artery and vein ligation, as previously described (55). After the vessel ligation,
mice were injected with a total volume of 50 μL of alginate gel containing 3 μg
of VEGF165 and/or 3 μg of IGF1, gel containing 3 μg of IGF1, gel with no GFs, or a
PBS solution containing 3 μg of VEGF165 and 3 μg of IGF1 directly into the gracilis
muscle (1–3 mm inside the muscle).
For analysis of reinnervation, hindlimb ischemia and gel delivery were
carried out as described in transgenic C57BL/6 mice selectively expressing YFP
under control of a thy-1 promoter in motoneurons (56).
Ischemia and Perfusion.Measurements of the ischemic/normal limb blood ﬂow
ratio were performed on anesthetized animals (n = 10) using an LDPI analyzer
(Perimed) (57).
Histologic Assessment of Skeletal Muscle.Micewere killed and hindlimbmuscle
tissues (n = 10 per time point per experimental condition) processed for his-
tologic analyses. The samples were stained with H&E, and ﬁber diameter and
the number of centrally located nuclei were analyzed as described (25). Vas-
cular endothelial cells were identiﬁed by immunostaining for mouse CD31 (BD
Biosciences Pharmingen). For measurement of capillary densities, histologic
analysis was performed in a blinded fashion as previously described (16). Im-
munostaining for Ki-67 (Ki-67 mouse IgG1; Dako) was performed to identify
cell proliferation. Qualitative analysis of apoptosis was assessed by TUNEL as-
say (Roche). Interstitial ﬁbrosis was morphometrically assessed in Masson Tri-
chrome (Sigma Aldrich) stained sections.
Analysis of Reinnervation. Mice were anesthetized by an i.p. injection of ket-
amine/xylazine and ﬁxed by transcardial injection of 4% paraformaldehyde.
The tibialis muscle was explanted and stained with Alexa594-bungarotoxin



















(Invitrogen) to visualize acetylcholine receptors. Innervation at the NMJ was
imaged using a Zeiss Pascal 5 LSM upright laser scanning confocal microscope
using anAr laser to exciteYFP at 488nm, andanHe/Ne laser to exciteAlexa594
bungarotoxin at 543 nm. At least 50 NMJs were counted for each condition.
Statistical signiﬁcance was determined using unpaired ANOVA analysis.
Mechanical Measurements. Intact gracilis and tibialis muscles were dissected
(n = 5/condition), mounted vertically midway between two cylindrical par-
allel steel wire electrodes (1.6 mm diameter, 21 mm long) attached by their
tendons to microclips connected to a force transducer (FORT 25, WPII) and
bathed in a physiologic saline solution (58) in a chamber oxygenated with 95%
O2/5% CO2 at 25°C. Muscle length was adjusted until maximum twitch force
was achieved (100–300 Hz). A wave pulse was initiated using a custom-written
LabVIEW program and delivered to the stimulation electrodes via a purpose-
built power ampliﬁer (QSC USA 1310). Contractions were evoked every 5 min.
Tetani were usually evoked at 300 Hz, 15–20 V, with constant pulse width and
train duration of 2 ms and 1 s, respectively. Peak tetanic force was determined
as the difference between the maximum force during a contraction and the
baseline level, and speciﬁc force calculated by normalization bymuscle weight.
Statistical Analyses. All results are expressed as mean ± SD. Multivariate re-
peated-measures ANOVA was performed to test for interactions between con-
ditions. Differences between conditions were considered signiﬁcant at P < 0.05.
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